

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 February 2004 (12.02.2004)

PCT

(10) International Publication Number
WO 2004/012757 A2

(51) International Patent Classification⁷: **A61K 38/17**,
A61P 33/02, A01K 67/027, G01N 33/92

(21) International Application Number:
PCT/BE2003/000131

(22) International Filing Date: 4 August 2003 (04.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2002/0465 2 August 2002 (02.08.2002) BE
2002/0649 14 November 2002 (14.11.2002) BE

(71) Applicant (for all designated States except US): UNIVER-
SITE LIBRE DE BRUXELLES [BE/BE]; Avenue F. D.
Roosevelt 50 CP 161, B-1050 BRUSSELS (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PAYS, Etienne


[BE/BE]; Place St Vincent 19, B-1457 NIL ST VIN-
CENT (BE). VANHAMME, Luc [BE/BE]; Avenue
des Combattants 170A, B-1490 COURT ST ETIENNE
(BE). PATURIAUX-HANOCQ, Françoise [BE/BE];
Avenue Minerve 27 (bte 32), B-1190 BRUSSELS (BE).
POELVOORDE, Philippe [BE/BE]; Rue de la Croix
Rouge 41, B-7712 HERSEAUX (BE).

(74) Agents: VAN MALDEREN, Joëlle et al.; OFFICE VAN
MALDEREN, Place Reine Fabiola 6/1, B-1083 BRUS-
SELS (BE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: APOLIPOPROTEIN L-I AND/OR DERIVATED POLYPEPTIDE FOR THE TREATMENT OF AND/OR THE PRE-
VENTION OF DISEASES INDUCED BY TRYPANOSOMA



(57) Abstract: The present invention is related to a composition comprising apolipoprotein L-I, the use of apolipoprotein L-I or a derivated polypeptide for the diagnostic, the treatment and/or the prevention of diseases induced in mammals by Trypanosoma. Another aspect is related to a transgenic non-human mammal comprising a polynucleotide expressing said apolipoprotein or a derivated polypeptide and which is tolerant or resistant to said Trypanosoma infection.